- Telehealth Visits
- Insurance plan information
Gabriel Loeb, MD, PhD
Nephrology- Telehealth Visits
- Insurance plan information
Kidney Disease (Nephrology) Parnassus
Gabriel Loeb, MD, PhD
NephrologyKidney Disease (Nephrology) Parnassus
- Telehealth Visits
- Insurance plan information
On this page
Education & training
Board certification
- Nephrology, American Board of Internal Medicine/Nephrology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Nephrology, UCSF Graduate Medical Education
Residency
- Internal Medicine, Brigham and Womens Hospital GME
Internship
- Internal Medicine, Brigham and Womens Hospital GME
Degree
- MD, Weill Cornell Graduate School of Medical Sciences
My expertise
Specialties
- Nephrology
Locations
Component Name: Provider Research Listing component built but no clinical trials or publications to display
Clinical Trials query: q=health_gateway_id_ss%3A%28%223186%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%223186%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.